Meeder Asset Management Inc. grew its holdings in shares of Syneos Health, Inc. (NASDAQ:SYNH – Get Rating) by 181.8% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 465 shares of the company’s stock after buying an additional 300 shares during the period. Meeder Asset Management Inc.’s holdings in Syneos Health were worth $33,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. CWM LLC lifted its position in shares of Syneos Health by 124.7% in the 2nd quarter. CWM LLC now owns 418 shares of the company’s stock worth $30,000 after purchasing an additional 232 shares during the period. First Horizon Advisors Inc. boosted its position in Syneos Health by 306.6% during the 2nd quarter. First Horizon Advisors Inc. now owns 496 shares of the company’s stock valued at $35,000 after acquiring an additional 374 shares in the last quarter. CENTRAL TRUST Co purchased a new position in shares of Syneos Health during the 1st quarter worth approximately $44,000. Lazard Asset Management LLC bought a new position in shares of Syneos Health in the 1st quarter worth approximately $53,000. Finally, Lansing Street Advisors purchased a new position in shares of Syneos Health in the 1st quarter valued at approximately $59,000. Hedge funds and other institutional investors own 94.80% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of equities analysts have issued reports on the company. Barclays decreased their price objective on Syneos Health from $60.00 to $30.00 and set an “overweight” rating for the company in a report on Sunday, November 6th. JPMorgan Chase & Co. cut shares of Syneos Health from an “overweight” rating to a “neutral” rating and cut their price objective for the stock from $85.00 to $53.00 in a report on Tuesday, October 18th. UBS Group assumed coverage on shares of Syneos Health in a report on Wednesday, September 7th. They set a “neutral” rating and a $68.00 target price for the company. William Blair downgraded Syneos Health from an “outperform” rating to a “market perform” rating in a research note on Wednesday, August 3rd. Finally, Citigroup reduced their price objective on Syneos Health from $55.00 to $30.00 and set a “neutral” rating for the company in a research report on Sunday, November 6th. Seven equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, Syneos Health presently has an average rating of “Hold” and a consensus target price of $56.90.
Syneos Health Price Performance
Syneos Health Profile
Syneos Health, Inc provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in the Phase I to IV of clinical development.
- Get a free copy of the StockNews.com research report on Syneos Health (SYNH)
- Wayfair Still Has Its Fair Share of Issues
- Why did NIO take a $581.11 million loss last quarter?
- Take Two Interactive Software Stock is Taking One Step Back
- This Mid-Cap Tech Stock Embodies Diversified Growth
- Is It Time To Take A Ride With Joby Aviation’s EV Innovations?
Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.